相关实验视频
Updated: Jul 6, 2025

05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
170
纳米技术在阿尔茨海默病的诊断和治疗中
1National Institute of Pharmaceutical Education and Research, SAS Nagar, Mohali, Panjab 160012, India.
Biochimica et biophysica acta. General subjects
|January 8, 2024
概括
纳米技术为早期阿尔茨海默病 (AD) 检测和治疗提供了有希望的解决方案. 先进的纳米技术工具使精确的药物输送通过血脑屏障,以改善神经退行性疾病管理.
科学领域:
- 神经科学是一个神经科学.
- 生物技术是生物技术.
- 材料科学 材料科学 材料科学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其特征是粉样质斑块,神经纤维状,神经元损失和认知能力下降.
- 目前的诊断方法缺乏早期阿尔茨海默病检测的敏感性,现有的治疗方法只提供症状缓解,而不解决根本原因.
- 有效的AD治疗需要在中枢神经系统 (CNS) 内的最佳药物度,需要克服血脑屏障 (BBB) 的策略.
研究的目的:
- 探索纳米技术在诊断和治疗阿尔茨海默病中的各种应用.
- 审查纳米技术如何促进AD疾病修饰疗法的发展.
- 讨论纳米技术在早期阿尔茨海默病检测,中枢神经系统的向药物输送和神经解剖应用中的作用.
主要方法:
- 关于纳米技术在阿尔茨海默病研究中的应用现有文献的综述.
- 分析基于纳米技术的诊断工具,药物输送系统和神经解剖方法.
- 纳米载体的检查,以提供治疗剂,如抗粉样蛋白,抗,胆酶抑制剂,抗氧化剂和激素药物.
主要成果:
- 纳米技术使得高度敏感的分子检测能够用于早期AD诊断.
- 基于纳米技术的药物输送系统显示出有效向中枢神经系统治疗剂的潜力,克服了BBB.
- 结合诊断和治疗的治疗应用正在成为AD管理中的一个有希望的领域.
结论:
- 纳米技术在改变阿尔茨海默病的诊断和治疗方面具有显著的前景.
- 它为早期检测提供创新解决方案,在BBB范围内提供有针对性的药物,并开发疾病修饰治疗方法.
- 在纳米医学领域进行进一步的研究和开发对于推进AD管理和改善患者治疗结果至关重要.
相关概念视频
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Alzheimer's Disease: Overview
490
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
490

